Drug Profile
Interferon alpha-2b biosimilar - Proteos biotech
Latest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Proteos biotech
- Class Antineoplastics; Antivirals; Interferons; Recombinant proteins
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer; Hepatitis B; Hepatitis C
Most Recent Events
- 06 Jul 2015 Discontinued for Cancer in Spain (unspecified route) (Proteos biotech pipeline, July 2015)
- 06 Jul 2015 Discontinued for Hepatitis B in Spain (unspecified route) (Proteos biotech pipeline, July 2015)
- 06 Jul 2015 Discontinued for Hepatitis C in Spain (unspecified route) (Proteos biotech pipeline, July 2015)